ROVI: MESSAGES FROM THE INVESTOR DAY (ANÁLISIS BANCO SABADELL)
Highlights from the presentation during the company’s Investor Day: Guidance: ROVI reiterated its guidance’22 of mid-single-digit growth for operating revenues (between +0% and +10%; vs. +22% BS(e) and +25% consensus) which we still think is overly conservative. Long-term, the company highlights that it will manage to reach the targets it set for 2023 (€ 588-609 M of revenues and € 158 M of EBITDA ex R&D) already in 2021, which is already factored in to our estimates and those of the consensus.
Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.